Clinical Trial 18331

Cancer Type: Malignant Hematology
Interventions:

Study Type: Other
Phase of Study: NA
Investigators:

  • Claudio Anasetti

Overview

Study Title

Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

Summary

This study tests whether adding certain genetic factors to the process of picking a stem cell donor can decrease the chances that the patient's leukemia will come back after bone marrow transplantation. Stem cell donors are "matched" based on genes called human leukocyte antigens (HLA). Currently, donors are selected largely on the basis of HLA gene typing alone. There is published data to show that donors with specific other genes called killer immunoglobulin-like receptors (KIR) may protect AML patients from having their leukemia return after a transplant. In this study, the best HLA matched donors will be tested for the KIR genes. If there are more than one donor available, a recommendation will be provided to study doctors as to which donors have potentially favorable KIR genes. The study doctors may or may not choose to use this donor for transplant or not based on his/her own judgment. Transplant care will not change otherwise as a result of this study. This study is being done to demonstrate that AML patients who have donors with specific KIR and HLA genes will have a better outcome following transplant.

Objective

Primary: To determine if risk for relapse is lowered among patients with KIR advantageous donors.

Inclusion Criteria

  • The trial will recruit potential transplant eligible participants with AML in clinic. RECIPIENT CRITERIA:
  • Persons of all ages are eligible for this study.
  • Patient must have diagnosis of acute myelogenous leukemia (AML) at participating institutions. Patients with de novo AML or AML with preceding myelodysplastic syndrome (MDS) are eligible.
  • Must be a potential candidate for an unrelated transplantation procedure at the time of enrollment even though patient may not be eligible for transplantation in the future due to relapse or presence of co-morbidity(ies).
  • An unrelated donor does not need to be identified at the time of enrollment. If an HLA-compatible unrelated donor is not identified for the patient, the patient will be removed from the study.

  • Exclusion Criteria

  • Recipients with an available sibling donor matched at HLA-A, HLA-C, and HLA-DRB1 (excluding identical twin siblings).
  • Patients for whom post-transplant treatment is planned are not excluded from enrollment.
  • Patients with prior allogeneic hematopoietic cell transplantation for AML. Note: Patients who have undergone prior hematopoietic cell transplantation for a diagnosis other than AML are still eligible for this study.